AEON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AEON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AEON Biopharma's yield on cost for the quarter that ended in Dec. 2024 was 0.00.
The historical rank and industry rank for AEON Biopharma's 5-Year Yield-on-Cost % or its related term are showing as below:
For the Biotechnology subindustry, AEON Biopharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AEON Biopharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where AEON Biopharma's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of AEON Biopharma is calculated as
Yield-on-Cost | = | Dividend Yield % | * | (1 | + | Dividend Growth Rate)^5 |
AEON Biopharma (AMEX:AEON) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Thank you for viewing the detailed overview of AEON Biopharma's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.
Strathspey Crown Holdings Group, Llc | 10 percent owner | 4040 MACARTHUR BLVD., SUITE 210, NEWPORT BEACH CA 92660 |
Priveterra Sponsor, Llc | 10 percent owner | 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301 |
Daewoong Co., Ltd | 10 percent owner | 244, GALMACHI-RO, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO M5 13211 |
Alexander Blair Wilson | officer: Exec VP, CLO & Corp Secretary | 5 PARK PLAZA, SUITE 1750, IRVINE CA 92614 |
Chad Oh | officer: Chief Medical Officer | C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660 |
Marc Forth | director, officer: Chief Executive Officer | C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPOER BEACH CA 92660 |
Jost Fischer | director | C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BOULEVARD, SUITE 250, NEWPORT BEACH CA 92660 |
Oleg Grodnensky | 10 percent owner | 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301 |
Vikram Malik | 10 percent owner | 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614 |
Peter A Reynolds | officer: Chief Financial Officer | 27442 PORTOLA PARKWAY, SUITE 200, FOOTHILL RANCH CA 92610 |
Robert J Palmisano | director, 10 percent owner | 110 HARTWELL AVENUE, LEXINGTON MA 02173 |
Shelley B Thunen | director | C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656 |
Eric G Carter | director | C/O KING PHARMACEUTICALS, INC., 501 FIFTH STREET, BRISTOL TN 37620 |
Plc Barclays | 10 percent owner | 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP |
David Meredith | officer: Chief Legal Officer&Secretary | 300 SE 2ND STREET, SUITE 600, FORT LAUDERDALE FL 33301 |
From GuruFocus
By GuruFocus News • 02-15-2025
By GuruFocus Research • 08-01-2023
By GuruFocus News • 02-15-2025
By GuruFocus News • 03-03-2025
By GuruFocus Research • 11-15-2023
By GuruFocus News • 11-15-2024
By GuruFocus News • 12-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.